Amel Beshir Mohammed
Research Subjects
Amel Beshir Mohammed has a total of 22 co-authors. Here are the top co-authors by number of shared publications:
- Abebaw Yeshambel Alemu
Department of Epidemiology and Biostatistics, Institute of Public Health, College of Medicine and Health Sciences, University of Gondar, Gondar
1 shared publication - Catherine Pitt
Department of Global Health and Development, London School of Hygiene & Tropical Medicine, London, UK
1 shared publication - Debisa Eshatu Wendimu
Armauer Hansen Research Institute, Addis Ababa, Ethiopia
1 shared publication - Derese Bekele Daba
Malaria and Neglected Tropical Diseases, Armauer Hansen Research Institute, Addis Ababa, Ethiopia.
1 shared publication - Elizabeth Allen
London School of Hygiene & Tropical Medicine, London, UK
1 shared publication - Endalamaw Gadisa
Department of Malaria and Neglected Tropical Disease Research, Armauer Hansen Research Institute, Addis Ababa
1 shared publication
Latest Publications
- Open Access
- 17 February 2026
- Published by Oxford University Press (OUP) in British Journal of Dermatology
- Vol. 194 (6) , 1142-1150
Clinical and patient-reported outcomes of cutaneous leishmaniasis treatment in Ethiopia: a prospective observational cohort study from two referral hospitals
Background: Cutaneous leishmaniasis (CL) is a major public health concern, particularly in Ethiopia, where about 40 000 new cases occur annually, predominantly caused by Leishmania aethiopica. Clinical phenotypes include localized CL (LCL), mucocutaneous leishmaniasis (MCL) and diffuse CL (DCL). Despite the high disease burden, treatment options and high-quality data on treatment outcomes are limited. Objectives: To evaluate the effectiveness of standard treatments in Ethiopia to inform future clinical trials. Methods: We conducted an observational cohort study of patients with parasitologically confirmed cutaneous leishmaniasis at two specialized dermatology referral hospitals. Clinical- and patient-reported outcomes were assessed at baseline and at standardized times during follow-up. The primary clinical outcome measure (‘cure’) was complete re-epithelialization or flattening of the index lesion at day 90. Patient-reported outcomes were assessed using skin-specific and general quality-of-life scores. Results: We enrolled 666 participants from April 2022 to October 2023. Median patient age was 20 years (interquartile range 14–35) and 405 patients were male (60.8%). More than half (n = 372; 55.9%) had previously received traditional treatment for CL. Most participants had LCL (n = 390; 58.6%) or MCL (n = 261; 39.1%). Intramuscular sodium stibogluconate 20 mg kg–1 daily was the most frequently used systemic therapy, either alone or in combination with lesion-directed therapy (cryotherapy or intralesional sodium stibogluconate). At day 90, 28.3% (n = 83/293) of participants with LCL, 23.5% (v = 47/200) with MCL and 8% (n = 1/12) with DCL were deemed cured. By day 90, all patient-reported outcomes of skin health improved for those with LCL or MCL, but skin and CL-related quality-of-life scores did not improve for those with DCL. Most participants (n = 522/641; 81.4%) experienced at least one clinical adverse event and 7.2% (n = 46/641) had abnormal laboratory findings during treatment. Conclusions: Current treatment strategies have low cure rates in Ethiopia. Well-designed randomized controlled trials are urgently needed to improve management of CL caused by L. aethiopica.
- 17 February 2026
- Published by Oxford University Press (OUP) in British Journal of Dermatology
- Vol. 194 (6) , 1142-1150
Open AccessClinical and patient-reported outcomes of cutaneous leishmaniasis treatment in Ethiopia: a prospective observational cohort study from two referral hospitals
Background: Cutaneous leishmaniasis (CL) is a major public health concern, particularly in Ethiopia, where about 40 000 new cases occur annually, predominantly caused by Leishmania aethiopica. Clinical phenotypes include localized CL (LCL), mucocutaneous leishmaniasis (MCL) and diffuse CL (DCL). Despite the high disease burden, treatment options and high-quality data on treatment outcomes are limited. Objectives: To evaluate the effectiveness of standard treatments in Ethiopia to inform future clinical trials. Methods: We conducted an observational cohort study of patients with parasitologically confirmed cutaneous leishmaniasis at two specialized dermatology referral hospitals. Clinical- and patient-reported outcomes were assessed at baseline and at standardized times during follow-up. The primary clinical outcome measure (‘cure’) was complete re-epithelialization or flattening of the index lesion at day 90. Patient-reported outcomes were assessed using skin-specific and general quality-of-life scores. Results: We enrolled 666 participants from April 2022 to October 2023. Median patient age was 20 years (interquartile range 14–35) and 405 patients were male (60.8%). More than half (n = 372; 55.9%) had previously received traditional treatment for CL. Most participants had LCL (n = 390; 58.6%) or MCL (n = 261; 39.1%). Intramuscular sodium stibogluconate 20 mg kg–1 daily was the most frequently used systemic therapy, either alone or in combination with lesion-directed therapy (cryotherapy or intralesional sodium stibogluconate). At day 90, 28.3% (n = 83/293) of participants with LCL, 23.5% (v = 47/200) with MCL and 8% (n = 1/12) with DCL were deemed cured. By day 90, all patient-reported outcomes of skin health improved for those with LCL or MCL, but skin and CL-related quality-of-life scores did not improve for those with DCL. Most participants (n = 522/641; 81.4%) experienced at least one clinical adverse event and 7.2% (n = 46/641) had abnormal laboratory findings during treatment. Conclusions: Current treatment strategies have low cure rates in Ethiopia. Well-designed randomized controlled trials are urgently needed to improve management of CL caused by L. aethiopica.